



Heteropathogenic virulence and phylogeny reveal phased pathogenic metamorphosis in *Escherichia coli* O2:H6

Martina Bielaszewska^{1,†}, Roswitha Schiller^{1,2,†}, Lydia Lammers¹, Andreas Bauwens¹, Angelika Fruth³, Barbara Middendorf¹, M Alexander Schmidt⁴, Phillip I Tarr⁵, Ulrich Dobrindt^{1,2}, Helge Karch¹ & Alexander Mellmann^{1,*}

Abstract

Extraintestinal pathogenic and intestinal pathogenic (diarrheagenic) *Escherichia coli* differ phylogenetically and by virulence profiles. Classic theory teaches simple linear descent in this species, where non-pathogens acquire virulence traits and emerge as pathogens. However, diarrheagenic Shiga toxin-producing *E. coli* (STEC) O2:H6 not only possess and express virulence factors associated with diarrheagenic and uropathogenic *E. coli* but also cause diarrhea and urinary tract infections. These organisms are phylogenetically positioned between members of an intestinal pathogenic group (STEC) and extraintestinal pathogenic *E. coli*. STEC O2:H6 is, therefore, a heteropathogen, and the first such hybrid virulent *E. coli* identified. The phylogeny of these *E. coli* and the repertoire of virulence traits they possess compel consideration of an alternate view of pathogen emergence, whereby one pathogroup of *E. coli* undergoes phased metamorphosis into another. By understanding the evolutionary mechanisms of bacterial pathogens, rational strategies for counteracting their detrimental effects on humans can be developed.

Keywords heteropathogenicity; phased metamorphosis; phylogeny; Shiga toxin-producing *Escherichia coli*; uropathogenic *Escherichia coli*

Subject Categories Microbiology, Virology & Host Pathogen Interaction

DOI 10.1002/emmm.201303133 | Received 6 June 2013 | Revised 8 November 2013 | Accepted 11 November 2013 | Published online 10 January 2014

EMBO Mol Med (2014) 6, 347–357

Introduction

Escherichia coli are usually harmless inhabitants of the human gut. However, some members of this species have acquired

specific virulence attributes that allow them to cause intestinal as well as extraintestinal diseases in humans (Kaper *et al.*, 2004). One important and instructive group of intestinal pathogenic *E. coli* is the set of Shiga toxin (Stx)-producing *E. coli* (STEC). STEC cause diarrhea, bloody diarrhea, and, because of toxemia and not dissemination, the hemolytic uremic syndrome (HUS) (Kaper *et al.*, 2004; Karch *et al.*, 2005). *E. coli* O157:H7 is the most common human pathogenic STEC (Karch *et al.*, 2005), but a variety of non-O157:H7 STEC serotypes have also been isolated from patients (Karch *et al.*, 2005; Mellmann *et al.*, 2008; Bielaszewska *et al.*, 2013). These pathogens have acquired a rather stereotyped suite of virulence loci ('parallel evolution') (Reid *et al.*, 2000; Ogura *et al.*, 2009). Other well-defined intestinal *E. coli* pathogroups include enteropathogenic (EPEC), enterotoxigenic (ETEC), enteroinvasive (EIEC), enteroaggregative (EAEC), and adherent-invasive (AIEC) *E. coli* (Nataro & Kaper, 1998; Darfeuille-Michaud, 2002; Kaper *et al.*, 2004). Extraintestinal pathogenic *E. coli* (ExPEC) are classified as uropathogenic (UPEC), sepsis-associated, and meningitis-associated (MNEC) (Kaper *et al.*, 2004).

Escherichia coli virulence and phylogeny are intertwined. Each pathogenic *E. coli* group possesses 'signature' repertoires of virulence genes, which enable them to colonize and injure their host (Kaper *et al.*, 2004). While exceptions exist, particularly among ETEC (Turner *et al.*, 2006), strains within pathogroups are often phylogenetically closely related (Achtman *et al.*, 1983; Wirth *et al.*, 2006). Current concepts of pathogen emergence employ linear descent scenarios, where horizontal acquisition of pathogenicity islands, bacteriophages, and plasmids by non-pathogens results in phylogenetically fixed pathogroups (Dozois & Curtiss, 1999). Here, we determined the phylogenetic relationship of STEC O2:H6 isolated from patients with diarrhea to other intestinal and extraintestinal pathogenic *E. coli* and then characterized the O2:H6 virulence genes as well as their UPEC virulence potential. To our surprise, these

¹ Institute of Hygiene, University of Münster, Münster, Germany

² Institute of Molecular Infection Biology, University of Würzburg, Würzburg, Germany

³ National Reference Center for Salmonella and Other Bacterial Enteric Pathogens, Robert Koch Institute, Wernigerode, Germany

⁴ Institute of Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Münster, Germany

⁵ Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA

*Corresponding author. Tel: +49 251 83 52316; Fax: +49 251 83 55688; E-mail: mellmann@uni-muenster.de

[†]These authors contributed equally to this work.

analyses did not portray the linear emergence of pathogenicity by step-wise recombination events, but, instead, identified STEC O2:H6 as a 'transitional' pathogen in the process of morphing between pathogroups.

Results

Phylogeny of STEC O2:H6

Multilocus sequence typing (MLST) (Wirth *et al*, 2006) demonstrates that 13 STEC O2:H6 strains isolated between 2000 and 2009 from epidemiologically unrelated patients with non-bloody diarrhea, whose illnesses resolved without progression to HUS and whose stools contained no other intestinal pathogens belong to sequence type (ST) 141 (supplementary Table S1). This ST is only distantly related to the STs of the non-H6 STEC O2, and is not found among STEC causing HUS ('the HUSEC collection') (Mellmann *et al*, 2008), intestinal pathogenic *E. coli* strains of other pathogroups (EPEC, ETEC, EIEC, EAEC, AIEC), prototypic ExPEC (UPEC and MNEC) strains, and in a non-pathogenic *E. coli* K-12 (supplementary Table S1). Intriguingly, in the minimum spanning tree based on allelic profiles of the seven MLST housekeeping genes in combination with 53 genes encoding the bacterial ribosome protein subunits (rMLST) (Jolley *et al*, 2012) (supplementary Table S2), STEC O2:H6 is positioned between the HUSEC and ExPEC (including UPEC and MNEC) strains, in the proximity of AIEC (Fig 1). In further phylogrouping (Clermont *et al*, 2000), the STEC O2:H6 isolates localize to *E. coli* Reference (ECOR) (Selander *et al*, 1987) phylogenetic group B2, as do UPEC, MNEC (Table 1) and AIEC (Dreux *et al*, 2013). In contrast, non-H6 STEC O2 and STEC in the HUSEC collection (<http://www.ehec.org>) belong to phylogroups A, B1, and D (Table 1).

To more thoroughly analyze the phylogenetic relationships between STEC O2:H6, most closely related STEC (serotype O91:H21; ST442; Fig 1) and prototypic HUS-associated STEC, UPEC and AIEC, we used whole genome sequencing and a gene-by-gene analysis of in total 2827 open reading frames that were present in all 14 strains investigated (see supplementary Table S1). This analysis confirmed the intermediate positioning of STEC O2:H6 between the major HUS-associated STEC serotypes and UPEC. Interestingly, AIEC were grouped closely to UPEC (Fig 2).

Virulence gene census of STEC O2:H6

We next sought various virulence genes of STEC, other intestinal pathogenic *E. coli*, and ExPEC in the STEC O2:H6 isolates using PCR and sequencing. STEC loci, including a *stx*₂ allele (GenBank accession no. GU126552) that is subtyped as *stx*_{2b} encoding Stx2b (Scheutz *et al*, 2012), and *saa* (encoding STEC autoagglutinating adhesin; Saa) (Paton *et al*, 2001) were present in all STEC O2:H6 (Table 1). In contrast, we failed to find loci typical for EPEC, including genes of the locus of enterocyte effacement (LEE) (supplementary Table S3), which are in most, but not all, HUSEC (Mellmann *et al*, 2008). Also, none of the STEC O2:H6 possessed virulence factors typically found in ETEC (heat-labile and heat-stable enterotoxins), EIEC (the invasive plasmid pInV and *Shigella* enterotoxin 2), and EAEC (the EAEC heat-stable enterotoxin 1, *Shigella* enterotoxin 1, the autotransporters




Figure 1. Phylogenetic relationships of STEC O2:H6 to intestinal and extraintestinal pathogenic *Escherichia coli* and to *E. coli* K-12. Minimum spanning tree based on MLST and rMLST allelic profiles portraying the clonal relationships of STEC O2:H6 to HUS-associated STEC (HUSEC collection) (Mellmann *et al*, 2008), other intestinal pathogenic *E. coli* (EPEC, ETEC, EIEC, EAEC, AIEC), prototypic ExPEC including UPEC and MNEC isolates, and a non-pathogenic *E. coli* strain K-12 (MG1655). Isolates are described in supplementary Table S1. Each circle represents a given allelic profile (combination of MLST and rMLST loci) and is named with the MLST sequence type. The different groups of strains are distinguished by colors of the circles. The numbers on the connecting lines illustrate the number of differing alleles.

Pet and Pic, and the EAEC virulence plasmid) (Nataro & Kaper, 1998; Vila *et al*, 2000; Kaper *et al*, 2004) (supplementary Table S3).

Because of their phylogenetic positioning between HUSEC and ExPEC (Fig 1), and because *E. coli* O2:H6 have been isolated from patients with urinary tract infections (Johnson *et al*, 2005), we tested the STEC O2:H6 isolates for virulence factors of ExPEC. Indeed, all STEC O2:H6 contain virulence genes typical of UPEC (Table 1). These include putative or demonstrated urovirulence loci encoding toxins (α -hlyA, *cnf1*, *vat*, *clb* island) (Johnson, 1991; Johnson & Stell, 2000; Parreira & Gyles, 2003; Johnson *et al*, 2005; Nougayrède *et al*, 2006), adhesins (*pap* cluster, *sfaII* cluster, *hek*) (Korhonen *et al*, 1982; Johnson, 1991; Hacker *et al*, 1993; Dobrindt *et al*, 2002; Johnson *et al*, 2005), the contact-dependent inhibition phenotype (*cdiAB* cluster) (Aoki *et al*, 2005), and iron acquisition systems (*iro* cluster, yersiniabactin cluster) (Johnson & Stell, 2000;

Table 1. Virulence loci and phylogeny of STEC O2:H6 as compared to non-H6 STEC O2, HUSEC and prototypic UPEC and MNEC strains

Gene or gene cluster ^a of	Presence of the locus in strain(s) (% no. of strains) ^b										
	O2:H6 STEC	O2:H4 STEC	O2:H27 STEC	O2:H29 STEC	HUSEC STEC	536 UPEC	CFT073 UPEC	J96 UPEC	UT189 UPEC	S88 MNEC	IHE3034 MNEC
STEC											
<i>stx</i> ^c	13 (100) (<i>stx</i> _{2b})	+	+	+	42 (100) (<i>stx</i> _{1a} , <i>stx</i> _{1c} , <i>stx</i> _{2a} , <i>stx</i> _{2b} , <i>stx</i> _{2c} , <i>stx</i> _{2d})	–	–	–	–	–	–
<i>saa</i>	13 (100)	–	–	–	6 (14.3)	–	–	–	–	–	–
ExPEC											
<i>α-hlyA</i>	10 (76.9) ^d	–	–	–	1 (2.4)	+	+	+	+	–	–
<i>cnf1</i>	10 (76.9) ^d	–	–	–	0	–	–	+	+	–	–
<i>vat</i>	13 (100)	–	–	–	0	+	+	+	+	+	+
<i>clb</i> island	13 (100)	–	–	–	0	+	+	+	+	–	+
<i>pap</i> cluster	10 (76.9) ^d	–	–	–	0	+	+	+	+	+	–
<i>sfall</i> cluster	9 (69.2)	–	–	–	0	–	–	–	+	–	+
<i>hek</i>	10 (76.9) ^d	–	–	–	1 (2.4)	+	–	+	+	–	+
<i>cdiAB</i> cluster	13 (100)	–	–	+	6 (14.3)	+	+	+	+	–	–
<i>iro</i> cluster	12 (92.3)	–	–	–	0	+	+	+	+	+	+
<i>ybt</i> cluster	13 (100)	+	–	–	13 (31.0)	+	+	+	+	+	+
Phylogroup	B2	D	A	B1	A, B1, D	B2	B2	B2	B2	B2	B2
ST (MLST) ^e	141	405	10	515	See Fig 1	127	73	12	95	95	95

^aThe genes encode following proteins: *stx*, Shiga toxin; *saa*, STEC autoagglutinating adhesin; *α-hlyA*, *α*-hemolysin; *cnf1*, cytotoxic necrotizing factor 1; *vat*, vacuolating autotransporter toxin; *clb* island, colibactin; *pap* cluster, P fimbriae; *sfall* cluster, S fimbriae, subtype Sfall; *hek*, Hek adhesin; *cdiAB*, contact-dependent inhibition phenotype; *iro* cluster and *ybt* cluster, yersiniabactin siderophore systems.

^bIn STEC O2:H6 ($n = 13$) and HUSEC strains ($n = 42$), the number (%) of strains positive for the locus is shown; for non-H6 O2 STEC and UPEC and MNEC strains (each $n = 1$), the presence (+) or absence (–) of the gene is indicated.

^c*stx* subtypes are shown. *stx*₂ (GenBank accession no. GU126552) subtyped as *stx*_{2b} is present in all sequenced STEC O2:H6 (supplementary Table S1). For *stx* genes in HUSEC strains see <http://www.ehec.org> and (Mellmann et al, 2008). STEC O2:H4 lost *stx* before subtyping (*stx* subtype is not known (n.k.)).

^dThe genes are present in the same strains.

^eST, sequence type; MLST, multilocus sequence typing.

Dobrindt et al, 2002). Notably, these ExPEC virulence genes were rare in non-H6 STEC O2 and in strains of the HUSEC collection (Table 1).

As AIEC were also phylogenetically closely related to UPEC and to STEC O2:H6 (Figs 1 and 2), we further investigated whether STEC O2:H6 strains contain FimH belonging to the same clade as that possessed by UPEC and AIEC strains (Sepelhi et al, 2009). FimH is the adhesin subunit of the type 1 pili that mediate adherence and play an essential role in the invasive ability of AIEC (Boudeau et al, 2001). Comparative sequence analysis of FimH from the sequenced STEC O2:H6 strains (supplementary Table S1) and from the UPEC (strains 536, UT189, CFT073) and AIEC (strains LF82, LF73) reference strains showed the phylogenetic positioning of all FimH proteins of STEC O2:H6 in the S70/N78 FimH clade (supplementary Fig S1), which is typical for UPEC and AIEC (Dreux et al, 2013).

Expression of STEC and UPEC virulence genes in STEC O2:H6

All STEC O2:H6 expressed Stx, as evidenced by the cytotoxicity of their supernatants to Vero cells (reciprocal titer range, 8–256; median, 32), and Saa (supplementary Fig S2).

Nearly all of the identified UPEC virulence loci were also expressed by the cognate STEC O2:H6 isolates. Each of the ten STEC O2:H6 that harbored *α-hlyA* and *cnf1* (Table 1) produced *α*-hemolysin on blood agar and cytotoxic necrotizing factor (CNF) 1, detectable as an ~115-kDa band in an immunoblot (supplementary Fig S3). Each of the three *α-hlyA*-negative, *cnf1*-negative and *clb*-positive STEC O2:H6 (Table 1) produced colibactin, a hybrid polyketide-peptide cyclomodulin encoded by the *clb* island (Nougayrède et al, 2006). Similar to prototypic colibactin-producing MNEC strain IHE3034 (Nougayrède et al, 2006), each STEC O2:H6 strain arrested HeLa cells in the G2 phase of the cell cycle after 48 h and distended these epithelial cells and their nuclei, converting them into megalocytes (Fig 3). In the ten remaining *clb*-positive isolates, HeLa cell lysis caused by *α*-hemolysin confounded our attempts to study colibactin expression. Neither G2 arrest nor cell distension were elicited by a *clb*-negative, Stx2-producing STEC O2:H27 (Fig 3), excluding a contribution of Stx to these effects.

The contact-dependent growth inhibition phenotype (Aoki et al, 2005), encoded by the *cdiAB* cluster, was sought in three randomly selected STEC O2:H6 (Fig 4). Each of these strains inhibited growth of the target *E. coli* MG1655/pBluescript KS II(+) strain during the




Figure 2. Phylogenetic relationships of STEC O2:H6 to prototypic UPEC, AIEC and most closely related and prototypic HUS-associated STEC based on whole genome sequencing. Minimum spanning tree is based on allelic profiles of 2827 genes present in all strains investigated (see supplementary Table S1). The different pathotypes are distinguished by colors of the circles and the serotypes and strain numbers (in parentheses) are given.

6 h observation period, as did the prototypic *cdiAB*-harboring strain EC93 (Aoki *et al.*, 2005). In contrast, *cdiAB*-negative STEC O2:H27 had no inhibitory effect (Fig 4).

vat, encoding vacuolating autotransporter toxin (Vat) (Parreira & Gyles, 2003), was expressed in all 13 *vat*-positive STEC O2:H6 as demonstrated by the ability of culture supernatants to produce vacuoles in Chinese hamster ovary (CHO) cells (Fig 5).

P and S fimbriae were expressed in eight of ten and six of nine strains, harboring these respective loci (Table 1), as demonstrated by the ability of the bacteria to agglutinate human and bovine erythrocytes, respectively, in the presence of mannose (Blumer *et al.*, 2005). Thus, the UPEC virulence loci found in STEC O2:H6 are largely functional across the collection of strains that we studied.

Analysis of urovirulence of STEC O2:H6

The ability of randomly selected STEC O2:H6 isolates to cause urinary tract infection (UTI) was tested in an experimental murine model of ascending UTI. The bacterial numbers in the bladder and the kidneys were determined 72 h after infection (Fig 6). The prototypic UPEC strain 536 and STEC O2:H6 strain 05-00787 were recovered in nearly equal numbers from the bladder tissue (1×10^5 – 1×10^6 colony-forming units (CFU)/g bladder) (Fig 6A). Bladder colonization by STEC O2:H6 strains 04-00955 and 03-08304 resulted in 10-fold higher organ loads relative to UPEC 536. In all four cases, bacterial concentrations in the bladder tissue were significantly higher than after infection with non-pathogenic *E. coli* K-12 strain MG1655 (Fig 6A). All three STEC O2:H6 strains also colonized the kidneys as efficiently as UPEC strain 536 (Fig 6B). In contrast, strain MG1655 was unable to ascend to the kidneys (Fig 6B). Consequently, the potential of STEC O2:H6 strains to cause UTI in this model is comparable to that of classic UPEC strain 536.




Figure 3. Production of colibactin by STEC O2:H6. HeLa cells were cocultured with bacteria (4 h), washed and incubated in gentamicin-supplemented medium (48 h). The DNA content was determined by flow cytometry and morphological changes were assessed microscopically. Bar = 100 μ m.

A Uninfected (control) cells were mostly in the G1 phase of the cell cycle (2n DNA) and retained normal morphology.

B–C Cells infected with *clb*-positive STEC O2:H6 strain 05-00787 (B) or the prototypic *clb*-harboring strain IHE3034 (C) were arrested in the G2 phase (4n DNA) and converted into megalocytes. (The phenotype shown in (B) was produced by each of three *clb*-positive, α -*hlyA*-negative and *cnf1*-negative STEC O2:H6).

D Cells infected with *clb*-negative Stx2-producing O2:H27 isolate displayed neither G2 arrest nor distension.




Figure 4. Contact-dependent growth inhibition mediated by STEC O2:H6. Ampicillin-resistant target strain MG1655/pBluescript KS II(+) was cultured alone or in mixture with log-phase culture of each inhibitor (inhibitor-to-target ratio 50:1) including *cdiAB*-positive STEC O2:H6 strains 03-08304, 05-06793, 04-03909, prototypic *cdiAB*-harboring strain EC93, or *cdiAB*-negative STEC O2:H27. At each indicated time point, the growth of the target strain (CFU/ml) was determined by plating 10-fold culture dilutions on LB agar with ampicillin. Data represent means \pm standard deviations of three independent experiments. * $P < 0.01$ (unpaired Student's *t*-test), differences between growth of the target strain alone and in coculture with each respective inhibitor.

Discussion

The clinical significance of hybrid pathogens was clearly demonstrated by the deadly 2011 outbreak caused by *E. coli* O104:H4 (Bielaszewska et al, 2011; Frank et al, 2011; Karch et al, 2012). The outbreak started in Germany in May 2011 and subsequently spread to other European countries and North America, affecting in total nearly 4000 persons of which more than 900 developed HUS and 54 died (Karch et al, 2012). The outbreak strain uniquely combined virulence genes typical for STEC and EAEC and expressed the phenotypes that define these pathogroups including Stx2 production and aggregative adherence to intestinal epithelial cells (Bielaszewska et al, 2011; Brzuszkiewicz et al, 2011; Mellmann et al, 2011; Rasko et al, 2011), the features that likely increased its virulence. This outbreak, therefore, tragically illustrated that blended virulence profiles in enteric pathogens introduced into susceptible populations can have serious public health consequences (Karch et al, 2012). Moreover, this outbreak highlighted the lack of our knowledge of the basic principles of evolutionary trends of new pathogens as demonstrated by the fact that the origin of the *E. coli* O104:H4 hybrid and its evolutionary history remain obscure.

In this context, our identification of another hybrid pathogen, STEC O2:H6 in this study, and gaining insight into its evolutionary role is of particular importance, because we can determine the phylogenetic coordinates of its evolution. Also, STEC O2:H6 is the first hybrid pathogen to demonstrate pluripotential pathogenicity in intestinal and extraintestinal milieus, as predicted by its virulence repertoire. Specifically, STEC O2:H6 occupies an evolutionary and pathogenic interface between intestinal and extraintestinal pathogenic *E. coli*, and several lines of evidence corroborate this assignment: sequence typing, virulence genotyping and phenotyping, and the clinical potential. First, MLST/rMLST, employing sequences of a




Figure 5. Vacuolization induced by STEC O2:H6. CHO cells were exposed to sterile culture supernatants of tested strains and presence of vacuoles was sought microscopically after 24 h. Bar = 20 μ m.

A–B *vat*-positive STEC O2:H6 strains 05-00787 (A) and 05-06739 (B). (Vacuolization similar to that displayed by these two strains was elicited by all STEC O2:H6 isolates).
C *vat*-containing UPEC strain J96 (positive control).
D Uninfected cells (negative control).

sample of housekeeping and ribosomal genes scattered around a chromosomal backbone, agnostically placed these isolates between HUSEC and ExPEC (Fig 1). Also whole genome sequencing of STEC O2:H6, closely related HUS-associated STEC, and prototypic HUSEC, AIEC and UPEC strains positioned STEC O2:H6 separately from the other pathotypes in an intermediate position (Fig 2). Next, STEC O2:H6 contain UPEC and HUSEC virulence genotypes and phenotypes, using ascertainment independent of sequence typing, a finding that appears highly non-random. While it is possible that chance acquisition of a gene encoding Stx via phage transduction into either a commensal *E. coli* or an ExPEC could have resulted in STEC O2:H6, our data argue in favor of true UPEC/HUSEC heteropathogenicity. Specifically, the phylogeny places STEC O2:H6 at quite a distance from commensal *E. coli*, and at moderate distances from ExPEC (including UPEC) and from HUSEC (Fig 1). Hence, the STEC O2:H6 are incarnated as a phylogenetically recognizable group, and one that differs from UPEC (Figs 1 and 2). Also, an additional virulence gene found in a subset of HUSEC, *saa*, encoded independently on a plasmid (Paton et al, 2001) (unlike *stx* which is encoded on a bacteriophage that integrates into the chromosome) was present in all STEC O2:H6, in addition to the many UPEC virulence loci. This simultaneous convergence on UPEC and STEC phylogeny and virulence profiles is most simply explained by a phased transition from one group of pathogens to the other. This is also corroborated by the whole genome sequence data, where STEC O2:H6 strains represent a separate lineage (Fig 2) indicating that the core genome has




Figure 6. Urovirulence of STEC O2:H6 strains. Bladder (A) and kidney (B) colonization levels were determined 72 h after transurethral inoculation of mice with UPEC strain 536 (positive control), the STEC O2:H6 strains 05-00787, 04-00955, and 03-08304, or non-pathogenic *Escherichia coli* K-12 strain MG1655 (negative control). Horizontal bars represent the mean CFU number of each strain per gram of tissue; the whiskers display the respective standard error of the mean. Significant differences in the bacterial organ load compared to the negative control are indicated by asterisks.

co-evolved with the virulence attributes. Finally, the heteropathogenic clinical potential of STEC O2:H6 is demonstrated by their ability to cause diarrhea in the human host and experimental UTI in mice. The evolution of STEC O2:H6 via a phased pathotype transition is overall different from that of the *E. coli* O104:H4 hybrid, which combines an EAEC genomic background with the presence of *stx* characteristic of STEC. However, both evolutionary models of this pathogen (Brzuszkiewicz et al, 2011; Mellmann et al, 2011; Rasko et al, 2011) suggest a classic linear evolution from a progenitor with reduced intestinal virulence via loss and/or acquisition of various mobile elements such as bacteriophages, genomic islands or plasmids (Brzuszkiewicz et al, 2011; Mellmann et al, 2011; Rasko et al, 2011). AIEC are, similar to STEC O2:H6, phylogenetically located between ExPEC (including UPEC) and intestinal pathogenic *E. coli* (Fig 1). Our in-depth analysis based on the whole genome sequencing and core genome analysis corroborated this fact and positioned AIEC even closer to UPEC (Fig 2). These data, together with the recently published genome sequence of the prototypic AIEC isolate LF82 (Miquel et al, 2010), demonstrate the genetic hybrid character of AIEC. However, as AIEC strains have only been associated with Crohn's disease (Darfeuille-Michaud et al, 1998; Darfeuille-Michaud, 2002) and not detected in human extraintestinal diseases, they cannot be considered, in contrast to STEC O2:H6, as heteropathogens from the clinical standpoint.

The heteropathogenicity of *E. coli* O2:H6 has multiple implications for our conceptualization of bacterial evolution and pathogen emergence. First, and most significantly, the 'missing link' phylogeny and virulence traits of STEC O2:H6 suggest that pathogenic *E. coli* emerge not only by the simple linear acquisition of virulence loci by non-pathogenic *E. coli* strains. We speculate, based on our data, that one pathogroup gradually exchanges one suite of virulence loci for those of another pathogroup, as its core genome transitions simultaneously and in the same direction in a process of 'phased metamorphosis'. This emergence model differs considerably from a linear 'pathogenic stem cell' descent scenario because metamorphosis implies that a pathogenic *E. coli* in a given venue and phylogeny retains alternative virulence options. Certainly, the step-wise scenario whereby non-virulent (or less virulent) progenitors of pathogens acquire virulence genes resulting in pathogen emergence

(Dozois & Curtiss, 1999) is appropriate for tightly circumscribed groups of pathogens, such as the enterohemorrhagic *E. coli* (EHEC) 1 clade (Leopold et al, 2009) or the recent *E. coli* O104:H4 outbreak strain, where, most plausibly, an EAEC acquired a Stx2-encoding bacteriophage (Bielaszewska et al, 2011; Brzuszkiewicz et al, 2011; Mellmann et al, 2011; Rasko et al, 2011). We wish to note that the latter pathogen, while possessing blended genotypes and phenotypes of EAEC and STEC, has a largely linear descent method of evolution, because it is phylogenetically closely related to an EAEC prototype strain 55989 (Brzuszkiewicz et al, 2011; Mellmann et al, 2011; Rasko et al, 2011). However, linear models might not apply across the broader *E. coli* genospecies, where evolution and pathogen emergence might be more trabeculated. Our data are compatible with a recent description of the complex and highly interwoven evolutionary history of *E. coli* (Touchon et al, 2009), including the flow of specific 'highways' of gene exchange (Leopold et al, 2011).

Our data actually validate the concept that virulence is ordained by phylogeny as well as by genes encoding specific effector molecules (Whittam et al, 1993). Specifically, the phylogenetic positioning of the STEC O2:H6 isolates between STEC and ExPEC (including UPEC) (Figs 1 and 2) and their possession of virulence loci from both STEC and UPEC (Table 1), reflect the co-evolution of the core chromosome with the accrual of virulence traits of the two closest pathogroups. Notably, loci specific for other pathogroups, such as those common to EPEC, ETEC, EIEC, or EAEC, are not present.

Shiga toxin-producing *Escherichia coli* are rare among urinary strain set collections. Johnson et al (Johnson et al, 2002) screened 597 UPEC isolates, and found no STEC, even though presumably non-toxigenic *E. coli* O2:H6 might have been in this collection. Indeed, *E. coli* O2:H6 accounted for 2.9% of UPEC isolated by these investigators in another study (Johnson et al, 2005). STEC O2:H6 is also rare in fecal samples from patients with diarrhea (Piérard et al, 1990) and absent from the HUSEC collection (Mellmann et al, 2008). The paucity of these organisms in large strain collections prompts us to speculate that possession of traits of intestinal and urinary pathogroups might reduce the ability of an organism to cause disease in either venue. Nevertheless, the heteropathogenic potential of these strains is substantiated by their isolation as the only pathogens from stools of epidemiologically unrelated patients

with diarrhea in this study, and their identification as diarrheagenic in other studies (Piérard *et al*, 1990), and their ability to cause UTI in an animal model.

The heteropathogenic nature of STEC O2:H6 warrants additional comments. The transitional nature of phased metamorphosis differs from parallel and convergent evolution. Specifically, this model portrays pathogens evolving along a continuum, with the backbone changing in synchrony with virulence loci. Our data clearly recommend combining backbone phylogeny assignment by MLST/rMLST and whole genome sequencing with a broad spectrum virulence profiling to discern metamorphosis between *E. coli* pathogroups. While backbone analysis (i.e. the combination of MLST, rMLST and whole genome sequencing in this case) accomplishes phylogenetic positioning, its combination with virulence profiles provides a more textured picture of evolution, and enabled us to propose this alternate mechanism of pathogen emergence. Application of such orthogonal assessments to additional isolates in other serotypes should determine the extent to which other heteropathogenic *E. coli* are found among the *E. coli* species, an association that might be obscured by microbiologists' focusing only on diagnostically and pathogenetically relevant virulence factors.

In summary, STEC O2:H6 is an extant 'way station' between major groups of pathogenic *E. coli*. It affords a unique opportunity to study pathogen emergence via pathogroup conversion, and introduces phased metamorphosis as a new evolutionary concept. Broader surveys combining backbone phylogeny and systematic virulence gene enumeration will be needed to determine if this form of pathogen emergence via transition is a generalized process.

Materials and Methods

Bacterial strains

The STEC O2, other intestinal pathogenic *E. coli*, and ExPEC strains used in this study are listed in supplementary Table S1. Except for an STEC O2:H29 (Tasara *et al*, 2008) (gift of R. Stephan, University of Zürich, Zürich, Switzerland), all the other STEC O2 strains originated in Germany and represent all STEC of this serogroup recovered in the European authors' laboratories. HUSEC strains (Mellmann *et al*, 2008) and their characteristics are available at <http://www.ehec.org>. The MLST data and the phylogenetic groups of the EPEC, ETEC, EIEC, EAEC, AIEC, UPEC and MNEC strains, and *E. coli* K-12 strain MG1655 were derived from the published genome sequences at <http://www.ncbi.nlm.nih.gov>. *E. coli* strain EC93 used as a control in growth inhibition experiments has been previously described (Aoki *et al*, 2005) and was a gift of D. A. Low (University of California-Santa Barbara, Santa Barbara, CA, USA).

MLST, rMLST, PCR phylogrouping and whole genome sequencing

Internal fragments of seven housekeeping genes were sequenced (Wirth *et al*, 2006) and STs were assigned according to the *E. coli* MLST website (<http://mlst.ucc.ie/mlst/dbs/Ecoli>). Similarly, sequences of the 53 rMLST loci were determined, alleles were assigned in accordance to the rMLST database (Jolley *et al*, 2012) and listed in supplementary Table S2. The minimum spanning tree based on the MLST and rMLST allelic profiles (in total 60 loci, ca.

24.6 kb) was generated using the SeqSphere software version 0.9 beta (Ridom GmbH, Münster, Germany). Classification into ECOR phylogenetic groups A, B1, B2, and D was performed as described (Clermont *et al*, 2000). For whole genome shotgun sequencing of selected O2:H6 strains (see supplementary Table S1), sequencing libraries were prepared using the Nextera XT chemistry (Illumina Inc., San Diego, CA, USA) for either a 100 bp or a 250 bp paired-end sequencing run on an Illumina HiScanSQ or MiSeq sequencer in accordance to the manufacturer's recommendations (Illumina). After quality trimming using the default parameters of the CLC Genomic Workbench software (CLC bio, Arhus, Denmark) the sequencing reads were assembled using the CLC Genomic Workbench *de novo* assembler (CLC bio). Gene sequences for subsequent analyses were extracted from contigs using the Ridom Seqsphere software version 0.9 beta (Ridom GmbH). For the gene-by-gene core genome analysis as described (Mellmann *et al*, 2011), we included all genes present in all strains analyzed (see supplementary Table S1). The whole genome sequence reads have been deposited at ENA SRA (study accession no. PRJEB4756).

FimH sequencing

FimH protein sequences were derived from the whole genome sequences and translated using the Ridom Seqsphere software version 0.9 beta (Ridom GmbH). The Neighbor-joining tree of the FimH sequences was created using the MEGA software (Tamura *et al*, 2011). For comparison, the published sequences of AIEC/UPEC typical FimH alleles (Dreux *et al*, 2013) were included.

Genotypic characterization

We used published PCR methodologies to find evidence of putative virulence genes associated with STEC, such as those encoding toxins (*stx*, EHEC-*hlyA*, *cdt*-III, *cdt*-V and *subAB* operons), serine proteases (*espP*, *espI*), adhesins (*eae*, *saa*, *lpfA*_{O26}, *lpfA*_{O113}, *lpfA*_{O157-O141}, *lpfA*_{O157-O1154}, *efa1*, *sfpA*), LEE-encoded type III secretion system (*escV*) and secreted proteins (*espF*, *map*, *espG*) (Friedrich *et al*, 2003; Gauthier *et al*, 2003; Bielaszewska *et al*, 2004, 2005b; Dahan *et al*, 2004; Mairena *et al*, 2004; Paton *et al*, 2004; Toma *et al*, 2004; Brockmeyer *et al*, 2007), and with UPEC including *α-hlyA*, *cnf1*, *cdt*-I and *cdt*-IV operons, *vat*, *sat*, *pap* cluster (*papACEFGH*), *sfaAI*, *sfaII* cluster (*sfaAGSHII*), *focA*, *focG*, *sfrA*, and *hek* (Blum *et al*, 1995; Johnson & Stell, 2000; Dobrindt *et al*, 2001, 2002; Bielaszewska *et al*, 2004; Ewers *et al*, 2005), as well as genes encoding iron acquisition systems such as *iro* cluster (*iroNEDCB*), and the yersiniabactin cluster (*ybtS*, *ybtQ*, *ybtA*, *irp2*, *irp1*, *ybtU*, *ybtT*, *ybtE*, *fyuA*) (Karch *et al*, 1999; Sorsa *et al*, 2003). The yersiniabactin cluster is characteristic of UPEC and MNEC (Johnson & Stell, 2000; Dobrindt *et al*, 2002; Sorsa *et al*, 2003) but has also been found in a subset of STEC (Karch *et al*, 1999). Moreover, the presence of the *cdiAB* cluster and the *clb* island was sought using PCRs listed in supplementary Table S4; the specificity of amplicons from these PCRs introduced in this study was confirmed by sequence analysis using Sanger sequencing. In addition, STEC O2:H6 were PCR-tested for virulence loci typical for other intestinal pathogenic *E. coli* including ETEC (*elt* and *estI* encoding heat-labile and heat-stable enterotoxin, respectively), EIEC (*ial*, a marker for the virulence plasmid pInV, and *sen* encoding a homologue of *Shigella* enterotoxin 2), and EAEC

(*set1*, *astA*, *pic* and *pet* encoding *Shigella* enterotoxin 1, EAEC heat-stable enterotoxin 1, autotransporters Pic and Pet, respectively, and *aatA*, a marker for the EAEC virulence plasmid) (Nataro & Kaper, 1998; Vila *et al*, 2000).

Sequence analysis of *stx* genes

stx genes of six randomly selected STEC O2:H6 strains (supplementary Table S1) were amplified and Sanger sequenced; resulting sequences were analyzed using the SeqSphere software version 0.9 beta (Ridom GmbH) and homologies were sought in GenBank (<http://www.ncbi.nlm.nih.gov/BLAST>). The *stx*₂ sequence from strain 03-08304 (representative of those present in all six sequenced strains) (*stx*_{2b} subtype) was deposited in GenBank (accession no. GU126552).

Phenotype determinations

Stx titers were determined by Vero cell cytotoxicity (Bielaszewska *et al*, 2006), and production of α -hemolysin was determined on Columbia blood agar (Heipha, Heidelberg, Germany) after overnight incubation. Production of Saa and CNF1 was assayed by immunoblot (Paton *et al*, 2001). Briefly, lysates of overnight Luria-Bertani (LB) broth cultures were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), separated proteins were transferred to a membrane (Immobilon P, Roth, Karlsruhe, Germany) and probed with polyclonal mouse anti-Saa antibody (Paton *et al*, 2001) (a gift from J. C. Paton, Adelaide University, Adelaide, Australia) or monoclonal mouse antibody against CNF1 + CNF2 (clone JC4) (Abcam, Cambridge, UK). Bound antibodies were detected using alkaline phosphatase-conjugated goat anti-mouse IgG (Dianova, Hamburg, Germany).

Colibactin expression was tested (Nougayrède *et al*, 2006) using HeLa cells (ATCC CCL-2) maintained in Eagle minimum essential medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 1% non-essential amino acids (Cambrex Bioscience, Verviers, Belgium). For cell cycle analysis, the cells were cultured in 12-well plates seeded with 7.5×10^4 cells per well. Semiconfluent monolayers were infected with overnight LB broth cultures of tested isolates diluted in interaction medium (culture medium with 5% FCS) to a multiplicity of infection (number of bacteria per cell) $\sim 100:1$, and cocultured for 4 h (37°C, 5% CO₂). Cells were then extensively washed and incubated in full fresh medium supplemented with gentamicin (200 μ g/ml) for 48 h. After harvesting, the cells were stained with propidium iodide-containing Nicoletti buffer (Bielaszewska *et al*, 2005a) and the DNA content of the nuclei was analyzed by flow cytometry on FACScalibur (Becton Dickinson, Heidelberg, Germany) as described previously (Bielaszewska *et al*, 2005a). For the cell distension assay, HeLa cells (3×10^4 per well) were seeded into 24-well microtiter plates. Semiconfluent monolayers were exposed for 4 h to overnight bacterial cultures as described above, the cells were then washed, and incubated in full medium with gentamicin for 48 h; morphology of native cells was examined using a light microscope (Axiovert 40; Zeiss, Jena, Germany).

Contact-dependent growth inhibition was determined (Aoki *et al*, 2005) using three randomly selected *cdiAB*-positive STEC O2:H6 strains and an *cdiAB*-negative STEC O2:H27 strain as inhibitors and *E. coli* K-12 strain MG1655 transformed with pBluescript KS II(+)

(Stratagene, La Jolla, CA, USA) encoding ampicillin resistance as a target strain. Briefly, a log-phase LB broth culture of each inhibitor strain was mixed (ratio 50:1) with a stationary culture of *E. coli* MG1655/pBluescript KS II(+) and cocultured (37°C, 225 rpm) for 1.5, 3, 4.5, and 6 h. At each time point, growth of the target strain incubated with each inhibitor and alone (growth control) was determined (CFU/ml) by plating 10-fold dilutions of the cultures on LB agar with ampicillin (100 μ g/ml) (to which all inhibiting bacteria were susceptible).

To determine if the isolates expressed Vat, CHO-K1 cells (ACC 110; German collection of microorganisms and cell cultures, Braunschweig, Germany) were seeded in 24-well plates (4×10^3 cells per well) in Ham's F12 medium with 10% of FCS (Cambrex). The cells were incubated with sterile overnight culture supernatants of the strains for 24 h (37°C, 5% CO₂) and vacuoles were sought by microscopy (Axiovert 40).

Expression of P- and S-fimbriae was tested using mannose-resistant (1% D-mannose; Roth) slide agglutination of 5% suspensions of defibrinated human and bovine erythrocytes (Elocin Laboratory, München, Germany), respectively (Blumer *et al*, 2005).

Experimental murine model of ascending UTI

Mice experiments were performed according to the guidelines for the Care and Use of Laboratory Animals in compliance with German regulations (Tierschutzgesetz). Permission for this study was provided by the regional government (AZ 55.2-2531.01-53/09). Mice (C57BL/6; female, 6–7 weeks old) were obtained from Charles River Laboratories (Sulzfeld, Germany) and kept under specific pathogen-free conditions. For murine infection, the bacterial strains were grown overnight under aerated conditions in LB medium, harvested by centrifugation and resuspended in sterile saline to a concentration of 1×10^{10} to 1×10^{11} CFU/ml. Groups of 8–15 C57BL/6 mice were transurethrally inoculated with 5×10^8 – 5×10^9 CFU of strain 536 (UPEC, positive control), STEC O2:H6 strains 05-00787, 04-00955, or 03-08304, or non-pathogenic *E. coli* K-12 strain MG1655 (negative control) as previously described (Hagberg *et al*, 1983). In each case, animals were sacrificed 72 h after infection. The bladder and kidneys were removed under sterile conditions, rinsed extensively with 0.9% NaCl and homogenized mechanically in 1 ml of 0.025% Triton-X 100, 0.9% NaCl. The number of bacteria was quantified by scoring CFU after overnight culture at 37°C on LB agar plates. The results were expressed as CFU/g of tissue. Statistically significant differences in colonization levels ($P < 0.05$) were assessed using Graphpad Prism 5 software. If the bladder challenge data were normally distributed, they were analyzed using an unpaired one-tailed *t*-test. Kidney infections were analyzed using the unpaired, non-parametric one-tailed Mann-Whitney test.

Supplementary information for this article is available online: <http://embomm.embopress.org>

Author contributions

HK, MB, AM and PIT designed experiments; MB, AM, LL, AB, AF, RS and BM performed experiments; MB, AM, HK, MAS, UD and PIT analyzed data; and AM, RS, MB, HK, UD and PIT wrote the manuscript.

The paper explained**Problem**

Classic evolutionary theory teaches that pathogens arise from non-pathogens by horizontal acquisition of virulence genes. This theory implies a unidirectional path to virulence, and a non-pathogen to pathogen gradient. Hybrid pathogens that combine virulence traits of different pathogroups can cause severe diseases in humans but their evolutionary history is poorly understood. Specifically, we do not know if they are 'weaponized' by the step-wise acquisition of virulence loci, or if pathogens transition from one pathogroup to another by multi-locus emergence.

Results

Shiga toxin-producing *E. coli* (STEC) O2:H6 are phylogenetically positioned between intestinal pathogenic STEC and uropathogenic *E. coli* (UPEC). They possess and express virulence factors associated with both STEC and UPEC. This hybrid causes both diarrhea and urinary tract infection. STEC O2:H6 are thus heteropathogens that occupy an evolutionary and pathogenic interface between intestinal and extraintestinal pathogenic *E. coli*. They are in a transitional evolutionary and virulence state.

Impact

The phylogeny and virulence potential of STEC O2:H6 compels us to propose a novel evolutionary concept whereby one pathogroup of *E. coli* undergoes phased metamorphosis into another. Improved understanding of evolutionary mechanisms of human pathogens could inspire novel strategies to predict pathogen emergence, and counteract their detrimental effects on human hosts.

Acknowledgements

We thank R. Stephan (University of Zürich, Switzerland), and D. A. Low (University of California, Santa Barbara, USA) for providing us with control strains, J. C. Paton (Adelaide University, Australia) for the Saa antibody, N. Brandt and M. Junge for skillful technical assistance, and D. A. Rudnick (Washington University, Saint Louis, USA) for helpful discussions. This study was supported by grants from the EU Network ERA-NET PathoGenoMics (no. 0313937C; to H.K. and M.A.S.) and ERA-NET PathoGenoMics 2 (no. 0315443; to A.M.), by a grant of the Medical Faculty Muenster (BD9817044, to A.M.), by grants from the Deutsche Forschungsgemeinschaft (DFG GRK 1409, to M.A.S. and H.K.; DFG Do 789/4-1, to U.D.; DFG Me 3205/2-1, to A.M.; DFG SFB 1009, to A.M, H.K., and U.D.), and P.I.T. was supported by National Institutes of Health Grant 5P30 DK052574 (Washington University Digestive Diseases Research Core Center).

Conflict of interest

The authors declare that they have no conflict of interest.

Data deposition

The *stx* sequence reported in this paper has been deposited in GenBank (accession no. GU126552) and the whole genome sequence reads have been deposited at ENA SRA (study accession no. PRJEB4756).

References

Achtman M, Mercer A, Kusecek B, Pohl A, Heuzenroeder M, Aaronson W, Sutton A, Silver RP (1983) Six widespread bacterial clones among *Escherichia coli* K1 isolates. *Infect Immun* 39: 315–335

- Aoki SK, Pamma R, Hernday AD, Bickham JE, Braaten BA, Low DA (2005) Contact-dependent inhibition of growth in *Escherichia coli*. *Science* 309: 1245–1248
- Bielaszewska M, Fell M, Greune L, Prager R, Fruth A, Tschäpe H, Schmidt MA, Karch H (2004) Characterization of cytolethal distending toxin genes and expression in Shiga toxin-producing *Escherichia coli* strains of non-O157 serogroups. *Infect Immun* 72: 1812–1816
- Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H (2006) Shiga toxin activatable by intestinal mucus in *Escherichia coli* isolated from humans: predictor for a severe clinical outcome. *Clin Infect Dis* 43: 1160–1167
- Bielaszewska M, Mellmann A, Bletz S, Zhang W, Kock R, Kossow A, Prager R, Fruth A, Orth-Holler D, Marejkova M et al (2013) Enterohemorrhagic *Escherichia coli* O26:H11/H⁻: a new virulent clone emerges in Europe. *Clin Infect Dis* 56: 1373–1381
- Bielaszewska M, Mellmann A, Zhang W, Köck R, Fruth A, Bauwens A, Peters G, Karch H (2011) Characterisation of the *Escherichia coli* strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. *Lancet Infect Dis* 11: 671–676
- Bielaszewska M, Sinha B, Kuczius T, Karch H (2005a) Cytolethal distending toxin from Shiga toxin-producing *Escherichia coli* O157 causes irreversible G2/M arrest, inhibition of proliferation, and death of human endothelial cells. *Infect Immun* 73: 552–562
- Bielaszewska M, Zhang W, Tarr PI, Sonntag A-K, Karch H (2005b) Molecular profiling and phenotype analysis of *Escherichia coli* O26:H11 and O26:NM: secular and geographic consistency of enterohemorrhagic and enteropathogenic isolates. *J Clin Microbiol* 43: 4225–4228
- Blum G, Falbo V, Caprioli A, Hacker J (1995) Gene clusters encoding the cytotoxic necrotizing factor type 1, Prs-fimbriae and alpha-hemolysin form the pathogenicity island II of the uropathogenic *Escherichia coli* strain J96. *FEMS Microbiol Lett* 126: 189–195
- Blumer C, Kleefeld A, Lehnen D, Heintz M, Dobrindt U, Nagy G, Michaelis K, Emödy L, Polen T, Rachel R et al (2005) Regulation of type 1 fimbriae synthesis and biofilm formation by the transcriptional regulator LrhA of *Escherichia coli*. *Microbiology* 151: 3287–3298
- Boudeau J, Barnich N, Darfeuille-Michaud A (2001) Type 1 pili-mediated adherence of *Escherichia coli* strain LF82 isolated from Crohns disease is involved in bacterial invasion of intestinal epithelial cells. *Mol Microbiol* 39: 1272–1284
- Brockmeyer J, Bielaszewska M, Fruth A, Bonn ML, Mellmann A, Humpf H-U, Karch H (2007) Subtypes of the plasmid-encoded serine protease EspP in Shiga toxin-producing *Escherichia coli*: distribution, secretion, and proteolytic activity. *Appl Environ Microbiol* 73: 6351–6359
- Brzuszkiewicz E, Thürmer A, Schuldes J, Leimbach A, Liesegang H, Meyer F-D, Boelter J, Petersen H, Gottschalk G, Daniel R (2011) Genome sequence analyses of two isolates from the recent *Escherichia coli* outbreak in Germany reveal the emergence of a new pathotype: Entero-Aggregative-Haemorrhagic *Escherichia coli* (EAHEC). *Arch Microbiol* 193: 883–891
- Clermont O, Bonacorsi S, Bingen E (2000) Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol* 66: 4555–4558
- Dahan S, Knutton S, Shaw RK, Crepin VF, Dougan G, Frankel G (2004) Transcriptome of enterohemorrhagic *Escherichia coli* O157 adhering to eukaryotic plasma membranes. *Infect Immun* 72: 5452–5459
- Darfeuille-Michaud A (2002) Adherent-invasive *Escherichia coli*: a putative new *E. coli* pathotype associated with Crohns disease. *Int J Med Microbiol* 292: 185–193

- Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, Gambiez L, Joly B, Cortot A, Colombel JF (1998) Presence of adherent *Escherichia coli* strains in ileal mucosa of patients with Crohns disease. *Gastroenterology* 115: 1405–1413
- Dobrindt U, Blum-Oehler G, Hartsch T, Gottschalk G, Ron EZ, Fünfstück R, Hacker J (2001) S-Fimbriae-encoding determinant *sfa(I)* is located on pathogenicity island III(536) of uropathogenic *Escherichia coli* strain 536. *Infect Immun* 69: 4248–4256
- Dobrindt U, Blum-Oehler G, Nagy G, Schneider G, Johann A, Gottschalk G, Hacker J (2002) Genetic structure and distribution of four pathogenicity islands (PAI I(536) to PAI IV(536)) of uropathogenic *Escherichia coli* strain 536. *Infect Immun* 70: 6365–6372
- Dozois CM, Curtiss R 3rd (1999) Pathogenic diversity of *Escherichia coli* and the emergence of exotic islands in the gene stream. *Vet Res* 30: 157–179
- Dreux N, Denizot J, Martinez-Medina M, Mellmann A, Billig M, Kisiela D, Chattopadhyay S, Sokurenko E, Neut C, Gower-Rousseau C et al (2013) Point mutations in FimH adhesin of Crohns disease-associated adherent-invasive *Escherichia coli* enhance intestinal inflammatory response. *PLoS Pathog* 9: e1003141
- Ewers C, Janssen T, Kiessling S, Philipp H-C, Wieler LH (2005) Rapid detection of virulence-associated genes in avian pathogenic *Escherichia coli* by multiplex polymerase chain reaction. *Avian Dis* 49: 269–273
- Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, et al (2011) Epidemic profile of Shiga-toxin-producing *Escherichia coli* O104:H4 outbreak in Germany. *N Engl J Med* 365: 1771–1780
- Friedrich AW, Borell J, Bielaszewska M, Fruth A, Tschäpe H, Karch H (2003) Shiga toxin 1c-producing *Escherichia coli* strains: phenotypic and genetic characterization and association with human disease. *J Clin Microbiol* 41: 2448–2453
- Gauthier A, Puente JL, Finlay BB (2003) Secretin of the enteropathogenic *Escherichia coli* type III secretion system requires components of the type III apparatus for assembly and localization. *Infect Immun* 71: 3310–3319
- Hacker J, Kestler H, Hoschützky H, Jann K, Lottspeich F, Korhonen TK (1993) Cloning and characterization of the S fimbrial adhesin II complex of an *Escherichia coli* O18:K1 meningitis isolate. *Infect Immun* 61: 544–550
- Hagberg L, Engberg I, Freter R, Lam J, Olling S, Svanborg Edén C (1983) Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic *Escherichia coli* of human origin. *Infect Immun* 40: 273–283
- Johnson JR (1991) Virulence factors in *Escherichia coli* urinary tract infection. *Clin Microbiol Rev* 4: 80–128
- Johnson JR, Jerome C, Boster DR, Stapleton AE, Tarr PI (2002) Analysis of urinary *Escherichia coli* isolates for ability to produce Shiga toxin. *J Clin Microbiol* 40: 2247–2248
- Johnson JR, Scheutz F, Ullery P, Kuskowski MA, O'Bryan TT, Sandberg T (2005) Host-pathogen relationships among *Escherichia coli* isolates recovered from men with febrile urinary tract infection. *Clin Infect Dis* 40: 813–822
- Johnson JR, Stell AL (2000) Extended virulence genotypes of *Escherichia coli* strains from patients with urosepsis in relation to phylogeny and host compromise. *J Infect Dis* 181: 261–272
- Jolley KA, Bliss CM, Bennett JS, Bratcher HB, Brehony C, Colles FM, Wimalathana H, Harrison OB, Sheppard SK, Cody AJ et al (2012) Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain. *Microbiology* 158: 1005–1015
- Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic *Escherichia coli*. *Nat Rev Microbiol* 2: 123–140
- Karch H, Denamur E, Dobrindt U, Finlay BB, Hengge R, Johannes L, Ron EZ, Tonjum T, Sansonetti PJ, Vicente M (2012) The enemy within us: lessons from the 2011 European *Escherichia coli* O104:H4 outbreak. *EMBO Mol Med* 4: 841–848
- Karch H, Schubert S, Zhang D, Zhang W, Schmidt H, Olschläger T, Hacker J (1999) A genomic island, termed high-pathogenicity island, is present in certain non-O157 Shiga toxin-producing *Escherichia coli* clonal lineages. *Infect Immun* 67: 5994–6001
- Karch H, Tarr PI, Bielaszewska M (2005) Enterohaemorrhagic *Escherichia coli* in human medicine. *Int J Med Microbiol* 295: 405–418
- Korhonen TK, Väisänen V, Saxén H, Hultberg H, Svenson SB (1982) P-antigen-recognizing fimbriae from human uropathogenic *Escherichia coli* strains. *Infect Immun* 37: 286–291
- Leopold SR, Magrini V, Holt NJ, Shaikh N, Mardis ER, Cagno J, Ogura Y, Iguchi A, Hayashi T, Mellmann A et al (2009) A precise reconstruction of the emergence and constrained radiations of *Escherichia coli* O157 portrayed by backbone concatenomic analysis. *Proc Natl Acad Sci USA* 106: 8713–8718
- Leopold SR, Sawyer SA, Whittam TS, Tarr PI (2011) Obscured phylogeny and possible recombinational dormancy in *Escherichia coli*. *BMC Evol Biol* 11: 183
- Mairena EC, Neves BC, Trabulsi LR, Elias WP (2004) Detection of LEE 4 region-encoded genes from different enteropathogenic and enterohemorrhagic *Escherichia coli* serotypes. *Curr Microbiol* 48: 412–418
- Mellmann A, Bielaszewska M, Köck R, Friedrich AW, Fruth A, Middendorf B, Harmsen D, Schmidt MA, Karch H (2008) Analysis of collection of hemolytic uremic syndrome-associated enterohemorrhagic *Escherichia coli*. *Emerg Infect Dis* 14: 1287–1290
- Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, Rico A, Prior K, Szczepanowski R, Ji Y, Zhang W et al (2011) Prospective genomic characterization of the German enterohemorrhagic *Escherichia coli* O104:H4 outbreak by rapid next generation sequencing technology. *PLoS ONE* 6: e22751
- Miquel S, Peyretailade E, Claret L, de Vallee A, Dossat C, Vacherie B, el Zineb H, Segurens B, Barbe V, Sauvanet P et al (2010) Complete genome sequence of Crohns disease-associated adherent-invasive *E. coli* strain LF82. *PLoS ONE* 5: e12714
- Nataro JP, Kaper JB (1998) Diarrheagenic *Escherichia coli*. *Clin Microbiol Rev* 11: 142–201
- Nougayrède J-P, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, Buchrieser C, Hacker J, Dobrindt U, Oswald E (2006) *Escherichia coli* induces DNA double-strand breaks in eukaryotic cells. *Science* 313: 848–851
- Ogura Y, Ooka T, Iguchi A, Toh H, Asadulghani M, Oshima K, Kodama T, Abe H, Nakayama K, Kurokawa K et al (2009) Comparative genomics reveal the mechanism of the parallel evolution of O157 and non-O157 enterohemorrhagic *Escherichia coli*. *Proc Natl Acad Sci USA* 106: 17939–17944
- Parreira VR, Gyles CL (2003) A novel pathogenicity island integrated adjacent to the *thrW* tRNA gene of avian pathogenic *Escherichia coli* encodes a vacuolating autotransporter toxin. *Infect Immun* 71: 5087–5096
- Paton AW, Sriramanote P, Talbot UM, Wang H, Paton JC (2004) A new family of potent AB(5) cytotoxins produced by Shiga toxicogenic *Escherichia coli*. *J Exp Med* 200: 35–46
- Paton AW, Sriramanote P, Woodrow MC, Paton JC (2001) Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxicogenic *Escherichia coli* strains that are virulent for humans. *Infect Immun* 69: 6999–7009

- Piérard D, Van Etterijck R, Breynaert J, Moriau L, Lauwers S (1990) Results of screening for verocytotoxin-producing *Escherichia coli* in faeces in Belgium. *Eur J Clin Microbiol Infect Dis* 9: 198–201
- Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin C-S, Iliopoulos D et al (2011) Origins of the *E. coli* strain causing an outbreak of hemolytic-uremic syndrome in Germany. *N Engl J Med* 365: 709–717
- Reid SD, Herbelin CJ, Bumbaugh AC, Selander RK, Whittam TS (2000) Parallel evolution of virulence in pathogenic *Escherichia coli*. *Nature* 406: 64–67
- Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S et al (2012) Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. *J Clin Microbiol* 50: 2951–2963
- Selander RK, Caugant DA, Whittam TS (1987) *Genetic Structure and Variation in Natural Populations of Escherichia coli*. pp 1625–1648. Washington, D.C.: American Society for Microbiology
- Sepehri S, Kotlowski R, Bernstein CN, Krause DO (2009) Phylogenetic analysis of inflammatory bowel disease associated *Escherichia coli* and the *fimH* virulence determinant. *Inflamm Bowel Dis* 15: 1737–1745
- Sorsa LJ, Dufke S, Heesemann J, Schubert S (2003) Characterization of an *iroBCDEN* gene cluster on a transmissible plasmid of uropathogenic *Escherichia coli*: evidence for horizontal transfer of a chromosomal virulence factor. *Infect Immun* 71: 3285–3293
- Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol* 28: 2731–2739
- Tasara T, Bielaszewska M, Nitzsche S, Karch H, Zweifel C, Stephan R (2008) Activatable Shiga toxin 2d (Stx2d) in STEC strains isolated from cattle and sheep at slaughter. *Vet Microbiol* 131: 199–204
- Toma C, Martínez Espinosa E, Song T, Miliwebsky E, Chinen I, Iyoda S, Iwanaga M, Rivas M (2004) Distribution of putative adhesins in different seropathotypes of Shiga toxin-producing *Escherichia coli*. *J Clin Microbiol* 42: 4937–4946
- Touchon M, Hoede C, Tenailon O, Barbe V, Baeriswyl S, Bidet P, Bingen E, Bonacorsi S, Bouchier C, Bouvet O et al (2009) Organised genome dynamics in the *Escherichia coli* species results in highly diverse adaptive paths. *PLoS Genet* 5: e1000344
- Turner SM, Chaudhuri RR, Jiang Z-D, DuPont H, Gyles C, Penn CW, Pallen MJ, Henderson IR (2006) Phylogenetic comparisons reveal multiple acquisitions of the toxin genes by enterotoxigenic *Escherichia coli* strains of different evolutionary lineages. *J Clin Microbiol* 44: 4528–4536
- Vila J, Vargas M, Henderson IR, Gascón J, Nataro JP (2000) Enterotoxigenic *Escherichia coli* virulence factors in travelers diarrhea strains. *J Infect Dis* 182: 1780–1783
- Whittam TS, Wolfe ML, Wachsmuth IK, Orskov F, Orskov I, Wilson RA (1993) Clonal relationships among *Escherichia coli* strains that cause hemorrhagic colitis and infantile diarrhea. *Infect Immun* 61: 1619–1629
- Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MC, Ochman H et al (2006) Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol Microbiol* 60: 1136–1151